Clinical study of azithromycin

Yoshiro Sawae; Hiroyasu Misumi; Koji Takaki; Toshiyuki Ishimaru; Masaharu Motomura; Yukio Kumagai; Makoto Katsuno; Nobuyuki Shimono; Hiroshi Inoue; Ikuo Sumita; Takatoshi Inoue

doi:10.11250/chemotherapy1995.43.Supplement6_415

Clinical study of azithromycin

Yoshiro Sawae, Hiroyasu Misumi, Koji Takaki, Toshiyuki Ishimaru, Masaharu Motomura, Yukio Kumagai, Makoto Katsuno, Nobuyuki Shimono, Hiroshi Inoue, Ikuo Sumita, Takatoshi Inoue

General Internal Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

A clinical study of azithromycin (AZM), a newly developed oral macrolide antibacterial agent, was performed with the following results. AZM at a dose of 250 or 500 mg was administered once a day for 3 days to 22 patients, including 1 case of pharyngolaryngitis, 4 of acute bronchitis and 17 of pneumonia. The clinical effect was evaluated as excellent in 5, good in 13, poor in 1 and undetermined in 3 cases. Adverse reactions thought to have a causal relationship to AZM included coughing, dyspnea and fever in 1 case and a rigidity of anterior chest in 1 case. However, these symptoms disappeared within 1 month after the administration of AZM. Abnormal laboratory values due to drug administration were observed in 3 cases: increased eosinophils in 2, elevated GOT, GPT, ALP, γ-GTP, CRP and ESR in 1.

Original language	English
Pages (from-to)	415-419
Number of pages	5
Journal	Japanese Journal of Chemotherapy
Volume	43
DOIs	https://doi.org/10.11250/chemotherapy1995.43.Supplement6_415
Publication status	Published - 1995

All Science Journal Classification (ASJC) codes

Pharmacology
Pharmacology (medical)

Access to Document

10.11250/chemotherapy1995.43.Supplement6_415

Cite this

@article{42878dc65a5147bf94667d4ee2edaa66,

title = "Clinical study of azithromycin",

abstract = "A clinical study of azithromycin (AZM), a newly developed oral macrolide antibacterial agent, was performed with the following results. AZM at a dose of 250 or 500 mg was administered once a day for 3 days to 22 patients, including 1 case of pharyngolaryngitis, 4 of acute bronchitis and 17 of pneumonia. The clinical effect was evaluated as excellent in 5, good in 13, poor in 1 and undetermined in 3 cases. Adverse reactions thought to have a causal relationship to AZM included coughing, dyspnea and fever in 1 case and a rigidity of anterior chest in 1 case. However, these symptoms disappeared within 1 month after the administration of AZM. Abnormal laboratory values due to drug administration were observed in 3 cases: increased eosinophils in 2, elevated GOT, GPT, ALP, γ-GTP, CRP and ESR in 1.",

author = "Yoshiro Sawae and Hiroyasu Misumi and Koji Takaki and Toshiyuki Ishimaru and Masaharu Motomura and Yukio Kumagai and Makoto Katsuno and Nobuyuki Shimono and Hiroshi Inoue and Ikuo Sumita and Takatoshi Inoue",

year = "1995",

doi = "10.11250/chemotherapy1995.43.Supplement6_415",

language = "English",

volume = "43",

pages = "415--419",

journal = "Japanese Journal of Chemotherapy",

issn = "1340-7007",

publisher = "Japan Society of Chemotherapy",

}

TY - JOUR

T1 - Clinical study of azithromycin

AU - Sawae, Yoshiro

AU - Misumi, Hiroyasu

AU - Takaki, Koji

AU - Ishimaru, Toshiyuki

AU - Motomura, Masaharu

AU - Kumagai, Yukio

AU - Katsuno, Makoto

AU - Shimono, Nobuyuki

AU - Inoue, Hiroshi

AU - Sumita, Ikuo

AU - Inoue, Takatoshi

PY - 1995

Y1 - 1995

N2 - A clinical study of azithromycin (AZM), a newly developed oral macrolide antibacterial agent, was performed with the following results. AZM at a dose of 250 or 500 mg was administered once a day for 3 days to 22 patients, including 1 case of pharyngolaryngitis, 4 of acute bronchitis and 17 of pneumonia. The clinical effect was evaluated as excellent in 5, good in 13, poor in 1 and undetermined in 3 cases. Adverse reactions thought to have a causal relationship to AZM included coughing, dyspnea and fever in 1 case and a rigidity of anterior chest in 1 case. However, these symptoms disappeared within 1 month after the administration of AZM. Abnormal laboratory values due to drug administration were observed in 3 cases: increased eosinophils in 2, elevated GOT, GPT, ALP, γ-GTP, CRP and ESR in 1.

AB - A clinical study of azithromycin (AZM), a newly developed oral macrolide antibacterial agent, was performed with the following results. AZM at a dose of 250 or 500 mg was administered once a day for 3 days to 22 patients, including 1 case of pharyngolaryngitis, 4 of acute bronchitis and 17 of pneumonia. The clinical effect was evaluated as excellent in 5, good in 13, poor in 1 and undetermined in 3 cases. Adverse reactions thought to have a causal relationship to AZM included coughing, dyspnea and fever in 1 case and a rigidity of anterior chest in 1 case. However, these symptoms disappeared within 1 month after the administration of AZM. Abnormal laboratory values due to drug administration were observed in 3 cases: increased eosinophils in 2, elevated GOT, GPT, ALP, γ-GTP, CRP and ESR in 1.

UR - http://www.scopus.com/inward/record.url?scp=0029591216&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029591216&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1995.43.Supplement6_415

DO - 10.11250/chemotherapy1995.43.Supplement6_415

M3 - Article

AN - SCOPUS:0029591216

SN - 1340-7007

VL - 43

SP - 415

EP - 419

JO - Japanese Journal of Chemotherapy

JF - Japanese Journal of Chemotherapy

ER -

Clinical study of azithromycin

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this